Sino Biopharmaceutical Ltd 2024 SR
The report highlights Sino Biopharmaceutical's 2024 ESG performance, focusing on its "CARE" strategy (Cure, Accessible, Relationship, Environmental). Key achievements include the launch of six innovative drugs, reaching over 160 million patients, and achieving its 2025 carbon reduction target ahead of schedule. The company also formalized its Carbon Neutrality Roadmap, aiming for group-wide carbon neutrality by 2050. Additionally, it invested RMB 60.11 million in social welfare and maintained high ESG ratings, including an MSCI "A" rating.
Company: Sino Biopharmaceutical Ltd
Sector: Health Care
Country: Hong Kong
Year: 2024
Type: SR
Pages: 90
Sino Biopharmaceutical Ltd
Environmental, Social And Governance Report
The report highlights Sino Biopharmaceutical's 2024 ESG performance, focusing on its "CARE" strategy (Cure, Accessible, Relationship, Environmental). Key achievements include the launch of six innovative drugs, reaching over 160 million patients, and achieving its 2025 carbon reduction target ahead of schedule. The company also formalized its Carbon Neutrality Roadmap, aiming for group-wide carbon neutrality by 2050. Additionally, it invested RMB 60.11 million in social welfare and maintained high ESG ratings, including an MSCI "A" rating.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 22, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees